We report our experience with oral busulfan (BU) in 159 consecutive patients to evaluate the safety of home administration. Patients received a myeloablative BUcontaining regimen, including oral anticonvulsant and antiemetic prophylaxis, followed by hematopoietic stem cell transplantation. Comprehensive verbal and written education was provided. Pharmacokinetic monitoring was performed and dose adjustments were made to target an area under the plasma concentration-time curve (AUC) of 900-1500 lmol.min/l. Safety was assessed by evaluating therapy-related toxicities, including seizures, venoocclusive disease (VOD) and patient tolerability. The utilization of pharmacokinetic monitoring was reviewed as a secondary end point. Of the 143 patients evaluated for BU-related seizures and VOD, only two (1.4%) experienced a generalized seizure and four patients (3%) were diagnosed with VOD. VOD resolved in three patients and was a contributing cause of death in one patient. Additional BU dosing owing to nausea and/or vomiting occurred in 28 patients (18%) and five patients (3%) were hospitalized. The median measured AUC was 1405 lmol. min/l, 68% of patients required a dose adjustment, and the median total administered BU dose was 13.6 mg/kg. In conclusion, high-dose oral BU can be safely administered on an outpatient basis.
Introduction
Busulfan (BU)-based chemotherapy is commonly used as conditioning treatment for hematopoietic stem cell transplantation (HSCT). Until the recent development of the intravenous (i.v.) formulation, BU was routinely administered orally (1 mg/kg) every 6 hours for 4 days in combination with other cytotoxic agents. Oral BU has high inter-patient variability, owing to poor gastrointestinal absorption and inconsistent hepatic first-pass metabolism, leading to the utilization of pharmacokinetic monitoring. Systemic BU exposure, expressed as area under the plasma concentration-time curve (AUC), has been directly correlated to transplant outcomes. A high AUC is associated with an increase in treatment-related toxicities, whereas lower levels are associated with treatment failure.
1-4 BU dose adjustments based on pharmacokinetic monitoring are shown to decrease adverse treatment-related toxicities and improve transplant outcomes.
Hepatic veno-occlusive disease (VOD) is the dose-limiting toxicity of BU and is reported to occur in 10-40% of patients. [5] [6] [7] [8] Other factors thought to contribute to the incidence of VOD include concomitant therapy with cyclophosphamide (Cy) and type of malignancy. 6, 7 Pharmacokinetic monitoring of oral BU has drastically decreased the incidence of VOD and improved transplant-related mortality. Grochow 9 showed a decrease in the incidence of VOD from 75 to 18%, when oral dose adjustments were made to target an AUC between 900 and 1500 mmol.min/l. Another study reported six out of 18 (33.3%) patients, with an initial AUC 41500 mmol.min/l, developing VOD versus one of 33 (3.0%) with an initial AUC o1500 mmol.min/l. 10 A study conducted by Deeg and co-workers 11 showed targeted BU dosing to be an effective conditioning regimen for patients with myelodysplastic syndrome undergoing a HLA-matched-related or -unrelated HSCT. Oral BU was adjusted to target an AUC of 800-900 mmol.min/l with similar relapse rates compared with traditional preparative regimens and lower treatment-related mortality. When administering oral BU, it is considered standard practice to monitor pharmacokinetics.
Recent studies show i.v. BU yields more reproducible pharmacokinetic parameters, but some variability remains owing to drug metabolism and clearance. In a pharmacokinetic analysis of 45 patients receiving i.v. BU (130 mg/m 2 / day for 4 days), de Lima and co-workers 12 reported an overall interdose variability of less than 10%. The mean AUC was 4891 mmol.min/l and ranged from 2931 to 8271 mmol.min/l. The desired AUC was 3600-6000 mmol. min/l, which was exceeded by 10% of patients without evidence of hepatic effects. Kashyap and co-workers 13 compared the incidence of VOD with oral versus i.v. BU in patients undergoing an allogeneic transplant. VOD devel-oped in five of 61 (8%) patients and 10 of 30 (33%) after i.v. and oral BU, respectively. We conducted a retrospective review of 159 consecutive patients who received comprehensive education and pharmacokinetic monitoring to evaluate the safety of administering oral BU in an outpatient setting.
Materials and methods
One hundred and fifty-nine patients were treated from March 1998 to September 2003 with a BU containing preparative regimen followed by HSCT. In addition to meeting routine clinical eligibility, patients were required to have an approved caregiver available on a 24-h basis, lodging within a 1 h driving radius of the HSCT clinic, and a signed informed consent. The feasibility of administering oral BU at home was included in the routine psychological assessment that all patients undergo before transplant at our center. Patients with potential noncompliance concerns were admitted to the hospital to receive oral BU under nursing supervision. Patients received comprehensive verbal and written chemotherapy education by a clinical pharmacist, including instructions on documenting all anticonvulsant and BU administration on a home medication administration record. Following the last dose of BU, a clinical pharmacist reviewed the administration record for completeness.
BU was administered as clear gelatin capsules, containing as many as seven 2 mg tablets, every 6 h for a total of 16 doses. BU pharmacokinetics was calculated following the first dose of BU, which was considered a test dose of 1 mg/ kg based on ideal body weight. Blood samples were drawn every 30 min for the first 180 min, then every 60 min until 480 min following the dose. The estimated steady-state AUC was calculated by adding the measured AUC (sum of ((C1 þ C2) (Dt)/2)) and infusion constant (tF inf ¼ C last /K e ), where C the concentration, Dt the change in time, tF inf the infusion constant and K e the elimination rate. Dose adjustments were made before the second dose, which was administered 36 h after the test dose. The desired AUC was 900-1500 mmol.min/l. Doses yielding an AUC outside of the desired range were adjusted to target an AUC of 1200 mmol.min/l. After dose adjustments were made, patients were instructed to take the remaining 15 doses of BU at home and return to the clinic in 4 days to begin i.v. chemotherapy. Patients were instructed to notify the on-call physician with concerns.
All patients received anticonvulsant and antiemetic prophylaxis before initiating BU. Phenytoin was administered at doses to maintain a therapeutic level of 10-20 mg/ ml. Gabapentin 300 mg orally three times daily was substituted for patients with phenytoin intolerance. Anticonvulsant prophylaxis was initiated the morning of the BU test dose and ended 24 h after the last dose of scheduled BU. Antiemetic therapy consisted of prochlorperazine 10 mg orally 30 min before each BU dose. If emesis occurred, repeat doses of oral BU were administered. A full dose was repeated if emesis occurred within 30 min and tablets/tablet fragments were found in the vomitus. Otherwise, only half the BU dose was repeated. Patients with persistent nausea and/or vomiting were hospitalized and converted into i.v. BU at the physician's discretion.
The primary aim was to evaluate the safety of administering oral BU in an outpatient setting. Safety was assessed by evaluating the incidence of seizures and VOD within 30 days post-HSCT. The Baltimore criteria were used to diagnose VOD (total bilirubin X2.0 mg/dl plus two of the following: ascites, X5% weight gain, or hepatomegaly). Patient tolerability was analyzed by the number of repeat BU doses secondary to emesis and hospitalizations requiring i.v. BU. A secondary objective was to evaluate the utility of pharmacokinetic analysis.
Results
One hundred and fifty-nine consecutive patients were treated with a BU containing preparative regimen followed by HSCT (Table 1) . Five patients were excluded owing to history of noncompliance (3), lack of outpatient insurance benefits (1) and hospital administration of i.v. BU secondary to a preexisting medical condition (1). The majority of patients received treatment for non-Hodgkin's lymphoma, multiple myeloma and acute myelogenous leukemia. There were 87 men and 72 women with a median age of 48 years. The preparative regimens most frequently administered were BUCyVP16 and BUCy. Ninety-seven patients underwent an autologous transplant, 61 patients an allogeneic transplant from a matched-related donor, and one patient an allogeneic transplant from a matched unrelated donor. The incidence of adverse events is shown in Table 2 . One hundred and forty-three patients were evaluated for the incidence of seizures and VOD. Eleven patients were excluded secondary to incomplete medical records (9) and expiring before day 30 (2). Ninety-five percent of patients received phenytoin for anticonvulsant prophylaxis. The measured total phenytoin concentration range was 3.5-23.5 mcg/ml, with a median of 12.8 mcg/ml. Two patients (1.4%) experienced a seizure. One patient with a history of a seizure disorder had a seizure the day after completing BU therapy. The other patient had a subtherapeutic phenytoin level of 9 mcg/ml. Four patients (3%) were diagnosed with VOD; two of the patients had documented lymphoma involvement of the liver before HSCT. VOD resolved in three patients and was a contributing cause of death in one patient. Four patients (2.6%) died from all causes by day 30 following transplant.
Information regarding repeat BU doses was available for 153 patients (Table 3) . Twenty-eight patients (18%) required a repeat BU dose ranging from one half-strength to three full-strength doses. The majority of patients required one full-strength dose and eight patients had more than one episode of vomiting. Five of the 28 patients with emesis were admitted to the hospital and four patients were converted to i.v. BU to complete therapy. Of note, two patients were admitted during oral busulfan secondary to a febrile episode.
The pharmacokinetic analysis is reviewed in Table 4 . BU test doses, based on IBW, ranged from 42 to 96 mg. The median AUC was 1405 mmol. min/l, ranging from 581 to 3030 mmol.min/l. Ninety-eight patients (68%) required a dose adjustment, with 59% of patients receiving a dose reduction. The median total BU dose administered was 13.8 mg/kg.
Discussion
Our analysis reveals that BU can be administered orally at home with a similar risk of adverse events compared with inpatient administration of oral and i.v. BU. The 3% incidence of VOD reported is lower than historical data with oral BU and comparable to published data with i.v. BU. It is worth noting that these patients were consecutive and not selected based on prognosis or mortality risk. There were more autologous transplants in this patient population, which may have contributed to low incidence of VOD. However, three of the four patients diagnosed with VOD received an autologous transplant. Patients received 15 of the 16 BU doses based on pharmacokinetic parameters. Following the test dose, patients returned to clinic the following day to begin the adjusted BU dose. This process shortens the exposure time of potentially elevated systemic levels and may contribute to the low incidence of VOD.
The incidence of seizure and emesis was also relatively low. Overall, 18% of patients had an episode of vomiting requiring them to repeat a partial or full BU dose. All patients were instructed to take prochloperazine 30 min before each dose of BU to reduce nausea and vomiting but compliance was not reported. Patients were also given lorazepam and prochlorperazine for home administration and extensively educated on emesis prophylaxis. In general, patients who begin taking antiemetics at the first sign of nausea tend to alleviate further episodes of nausea and vomiting. Compliance with emesis prophylaxis and treatment was not monitored and further evaluation of this may suggest ways to improve the incidence of emesis.
The pharmacokinetic analysis presented reiterates the necessity of BU monitoring when administered orally. Ninety-eight patients (68%) required a dose adjustment and the total BU dose administered was 6.9-22 mg/kg. The observation, combined with the fact that 86% of patients receiving a dose adjustment required a dose reduction, Pharmacokinetic values reported for both autologous and allogeneic transplant patients receiving BU. Note: Doses were adjusted to target AUC of 900-1500.
suggests that for patients who undergo pharmacokinetic monitoring the appropriate dose of oral BU should be less than 16 mg/kg. The majority of patients were administered phenytoin prophylaxis, which is reported to decrease plasma concentrations of BU by 15% or more. However, this potential drug interaction does not appear to be clinically significant. Finally, the cost of BU administration is a contributing factor. Comparing average wholesale prices, i.v. Busulfex is roughly five times more expensive then oral BU. As both methods are currently used along with pharmacokinetic monitoring, the additional laboratory costs are irrelevant. In addition, the ability to keep HSCT patients in an outpatient setting appears to be associated with equivalent or superior outcomes compared to inpatient care. 14, 15 Therefore, it is important to review the safety and feasibility of oral administration. Overall, our experience shows that oral BU can be safely administered at home when combined with pharmacokinetic monitoring and extensive education.
